Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential dapagliflozin plus basal insulin after 1 week of intensive insulin therapy in uncontrolled type 2 diabetes
ChiCTR1900021490Phase 4Recruiting
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Start
- Jul 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin and human insulin in type 2 diabetes mellitus (T2DM), sponsored by The Third Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Fasting blood glucose and Postprandial blood glucose. Started Jul 2019; status: recruiting.
02
Drugs
dapagliflozinhuman insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900021490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021490.